NCT07097987Completed
Evaluation of the Efficacy of the Composite WM Formula in Promoting GLP-1 Secretion
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate the physiological effects of a WM Formula on glucagon-like peptide-1 (GLP-1) secretion and glycemic regulation in adults with elevated body fat percentage. The WM Formula is a multi-component dietary supplement composed of Bifidobacterium breve (Active), Rocket Apple Extract Powder (Active), Probio-kombu Black Tea Powder (Active), Soy Protein (Excipient), Gum Acacia (Excipient), and Erythritol (Excipient). Participants enrolled in the study will be required to undergo blood collection, height measurement, body composition analysis, and questionnaire completion. Each testing session will take approximately 5 hours, and participants will need to complete two trial visits in total. There will be a 7-day washout period between the two trial sessions (i.e., after completion of the first trial, the second trial will be scheduled at least 7 days later). On each trial day, blood samples and relevant assessments will be conducted at the following time points: before ingestion of the test product or placebo, and at 15, 30, 45, 60, 90, 120, and 240 minutes post-ingestion.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 30 Jul 2025
- Start date
- Apr 2026
- Primary completion date
- Apr 2026
- Lead sponsor
- TCI Co., Ltd.
- Diseases
- Obesity
- NCT number
- NCT07097987
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From Apr 2026 to the primary completion date, Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Acute gastroenteritis within 2 weeks prior to study initiation.
- Known allergy to any ingredient in the investigational product.
Other illness
- History of chronic gastrointestinal disorders, seizure disorders or epilepsy, hepatic or renal diseases, malignancies, endocrine disorders, psychiatric illnesses, alcohol or drug abuse, or other major organic diseases based on medical history.
- History of gastrointestinal surgery, organ transplantation, or other major surgeries.
- History of hypoglycemia.
Lab values
- Use of GLP-1 receptor agonists approved in Taiwan (e.g., liraglutide, semaglutide, dulaglutide), blood glucose-regulating medications, weight loss-related drugs or functional foods, probiotics, or gastrointestinal health-related supplements or medications within 30 days prior to the start of the study.
Other
- Known lactose intolerance.
- Chronic diarrhea.
- Employees or immediate family members of TCI Co., Ltd.
Who the study is looking for
- Adults aged 18 years or older who are willing to sign the informed consent form.
- Body fat percentage: 30%-45% for females and 25%-40% for males, and BMI 23 - 34 kg/m2.
- Non-pregnant and non-lactating women who agree to use physical contraceptive methods (e.g., condoms, intrauterine devices) throughout the study period.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| TCI Co., Ltd. Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.